Arrowhead Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. 

CEO
Christopher Richard Anzalone
CEOChristopher Richard Anzalone
Employees
711
Employees711
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1989
Founded1989
Employees
711
Employees711

ARWR Key Statistics

Market cap
10.12B
Market cap10.12B
Price-Earnings ratio
-33.47
Price-Earnings ratio-33.47
Dividend yield
Dividend yield
Average volume
2.09M
Average volume2.09M
High today
$72.67
High today$72.67
Low today
$69.89
Low today$69.89
Open price
$71.96
Open price$71.96
Volume
1.86M
Volume1.86M
52 Week high
$87.83
52 Week high$87.83
52 Week low
$14.30
52 Week low$14.30

Stock Snapshot

The current Arrowhead Pharmaceuticals(ARWR) stock price is $71.00, with a market capitalization of 10.12B. The stock trades at a price-to-earnings (P/E) ratio of -33.47.

During the trading session on 2026-07-15, Arrowhead Pharmaceuticals(ARWR) shares reached a daily high of $72.67 and a low of $69.89. At a current price of $71.00, the stock is +1.6% higher than the low and still -2.3% under the high.

Trading activity shows a volume of 1.86M, compared to an average daily volume of 2.09M.

The stock's 52-week range extends from a low of $14.30 to a high of $87.83.

The stock's 52-week range extends from a low of $14.30 to a high of $87.83.

ARWR News

Investing.com 2d
Stifel initiates Arrowhead Pharma stock with buy rating on drug pipeline - Investing.com

...

Stifel initiates Arrowhead Pharma stock with buy rating on drug pipeline - Investing.com
TipRanks 2d
Arrowhead initiated with a Buy at Stifel

Stifel analyst James Condulis initiated coverage of Arrowhead (ARWR) with a Buy rating and $98 price target. SASHTA-3/4 results should establish plozasiran as “...

Simply Wall St 6d
Arrowhead Pharmaceuticals Is Up 6.6% After Russell Index Upgrade Has The Bull Case Changed?

On 27 June 2026, Arrowhead Pharmaceuticals, Inc. was removed from several Russell 2000 benchmarks and simultaneously added to larger Russell indices including t...

Arrowhead Pharmaceuticals Is Up 6.6% After Russell Index Upgrade Has The Bull Case Changed?

Analyst ratings

86%

of 14 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.